Transurethral Water Jet Ablation (Aquablation) for Benign Prostatic Hypertrophy
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - Rhode Island policy alerts
Know when Blue Cross Blue Shield - Rhode Island releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs coverage and medical criteria for transurethral waterjet ablation (Aquablation) to treat lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH) for Commercial Products of Blue Cross Blue Shield - Rhode Island.
No material clinical or coverage changes in this revision.
Coverage and Medical Necessity Criteria
Medical necessity criteria
Covered when ALL of the following are met:
Overall requirements
- A: a. Prostate volume of 30-150 cc
B
- i: International Prostate Symptom Score (IPSS) \u2265 12
- ii: Maximum urinary flow rate (Qmax) of \u2264 15 mL/s
- iii: Failure, contraindication, or intolerance to at least three months of conventional medical therapy for LUTS/BPH (e.g., alpha blocker, PDE5 inhibitor, finasteride/dutasteride).
Exclusions (must not have any)
- a: Body mass index \u2265 42 kg/m2
- b: Known or suspected prostate cancer or PSA > 10 ng/mL unless a negative prostate biopsy within the last 6 months
- c: Bladder cancer, neurogenic bladder, bladder calculus, or clinically significant bladder diverticulum
- d: Active urinary tract or systemic infection
- e: Treatment for chronic prostatitis
- f: Diagnosis of urethral stricture, meatal stenosis, or bladder neck contracture
- g: Damaged external urinary sphincter
- h: Known allergy to device materials
- i: Inability to safely stop anticoagulants or antiplatelet agents preoperatively
Individuals must NOT have any of the following for transurethral waterjet ablation (Aquablation) to be considered reasonable and necessary: BMI ≥ 42 kg/m2; known or suspected prostate cancer (per NCCN Prostate Cancer Early Detection guidelines) or PSA > 10 ng/mL unless a negative prostate biopsy was obtained within the prior 6 months; bladder cancer, neurogenic bladder, bladder calculus, or clinically significant bladder diverticulum; active urinary tract or systemic infection; treatment for chronic prostatitis; diagnosis of urethral stricture, meatal stenosis, or bladder neck contracture; damaged external urinary sphincter; known allergy to device materials; or inability to safely stop anticoagulants or antiplatelet agents preoperatively.
Treatment using a fluid jet system (Aquablation) will be considered not medically necessary when the medical criteria listed in this policy have not been met.
Coding and Key Clinical Thresholds
| 52597 | Transurethral robotic-assisted waterjet resection of prostate, including intraoperative planning, ultrasound guidance, control of postoperative bleeding, complete, including vasectomy, meatotomy, cystourethroscopy, urethral calibration and/or dilation, and internal urethrotomy, when performed (New Code Effective 1/1/2026) |
| 0421T | Transurethral waterjet ablation of prostate, including control of post-operative bleeding, including ultrasound guidance, complete (vasectomy, meatotomy, cystourethroscopy, urethral calibration and/or dilation, and internal urethrotomy are included when performed) (Code Deleted Effective 12/31/2025) |
Provider Requirements, Documentation, and Denial Triggers
Prior authorization recommended
Prior authorization is recommended for transurethral waterjet ablation (aquablation) for Commercial Products.
Medical therapy prerequisite — 3 months of conventional therapy
Patients must have persistent moderate to severe symptoms despite maximal medical management, including failure, contraindication, or intolerance to at least three months of conventional medical therapy (e.g., alpha blocker, PDE5 inhibitor, finasteride/dutasteride).
- Requirement applies to indication 1.b.iii in the medical necessity criteria.
Required clinical documentation
Document prostate volume (30–150 cc), IPSS score (≥ 12), maximum urinary flow rate (Qmax ≤ 15 mL/s), and details showing failure, contraindication, or intolerance to at least three months of conventional medical therapy. Also document that the device used is FDA approved/cleared and the absence of any listed exclusions.
- Prostate volume within 30–150 cc (criterion 1.a).
- IPSS ≥ 12 and Qmax ≤ 15 mL/s (criteria 1.b.i and 1.b.ii).
- Evidence of ≥3 months of prior medical therapy and reason for failure/contraindication/intolerance (criterion 1.b.iii).
- Confirmation device is FDA approved/cleared (criterion 2).
- Documentation demonstrating none of the exclusions apply (see exclusion list).
Denial triggers for medical necessity
Treatment will be considered not medically necessary — and may be denied — if the patient does not meet ALL required medical criteria or has any listed exclusion.
- Failure to meet ALL indication criteria: prostate volume 30–150 cc; IPSS ≥ 12; Qmax ≤ 15 mL/s; and failure/contraindication/intolerance to ≥3 months of conventional therapy.
- Presence of any exclusion such as BMI ≥ 42 kg/m2; known or suspected prostate cancer or PSA > 10 ng/mL without recent negative biopsy; bladder cancer, neurogenic bladder, bladder calculus, or significant diverticulum; active infection; chronic prostatitis treatment; urethral stricture, meatal stenosis, or bladder neck contracture; damaged external urinary sphincter; allergy to device materials; or inability to safely stop anticoagulants/antiplatelet agents.
- If the medical criteria above have not been met, treatment using the fluid jet system (Aquablation) is considered not medically necessary.
Background
Benign prostatic hyperplasia (BPH) commonly affects older men and can produce lower urinary tract symptoms (LUTS) that impair quality of life. Transurethral waterjet ablation (Aquablation) is a minimally invasive, robotically assisted fluid-jet tissue resection technique investigated as an alternative to transurethral resection of the prostate (TURP) and was cleared by the FDA (Aquabeam System) for resection and removal of prostate tissue causing LUTS/BPH. Coverage under this policy is for commercial members when the procedure is performed once and all medical criteria and exclusions are satisfied, including documented prostate volume, symptom severity, flow rate, prior medical therapy status, and absence of listed exclusions.
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.